Introduction
============

Non-small cell lung cancer (NSCLC) is a globally important cancer which remains a major cause of cancer related death despite advances in cancer treatment [@B1], [@B2]. In recent years, molecularly-targeted therapy has shown great promises in molecular subtypes of lung cancer patients. As an exemplar, EGFR-tyrosine kinase inhibitors (TKI) can prolong progression-free survival for EGFR-mutated lung cancer patients [@B3], [@B4]. However, the resistance to EGFR-TKI invariably emerged with the treatment [@B5]. Studying the mechanisms of resistance to EGFR-TKI has thus become a research focus in this field. Recent studies showed that EGFR-TKI resistance may be associated with EGFR T790M mutations [@B6]-[@B8], the activation of bypass pathways [@B9]-[@B11], abnormal downstream pathways [@B12], [@B13], impairment for EGFR-TKI mediated apoptosis [@B14],[@B15], histological transformation [@B16], drug transport [@B17], and etc. Other resistance mechanisms remain to be found.

Cyclooxygenase-2 (COX-2) regulates inflammation [@B18]. COX-2 plays an important role in carcinogenesis by stimulating growth, survival, invasion, metastasis, and angiogenesis of tumor cells [@B19]-[@B22], [@B23], [@B24]. EGFR signaling and COX-2 have known interactions in cancer cells [@B25]-[@B27]. Young et al showed that COX-2 activation negatively regulates EGFR, and that its overexpression contributes to gefitinib resistance [@B28].

Here, we show that COX-2 is overexpressed in NSCLC cells that show resistance to gefitinib-therapy. We further demonstrate that COX-2 mediates gefitinib resistance through its interactions with EGFR that ultimately activate PI3K-AKT signaling. These data identify COX-2 as a novel therapeutic target to overcome NSCLC drug resistance.

Materials and Methods
=====================

Tissues and ethics
------------------

The study was approved by our local ethics committee at the Shanghai Pulmonary Hospital, Tongji University School of Medicine. Our study included 32 patients with NSCLC who received gefitinib treatment and developed acquired resistance eventually. NSCLC was diagnosed through pathological assessments. Clinical and demographic data were collected (Table [1](#T1){ref-type="table"}). Informed consent was provided by all participants. Enrolled patients provided written informed consent.

NSCLC cells and culture
-----------------------

The human lung cancer cell lines H1299, H460, SK-MES-1, A549 cells and normal human bronchial epithelial cells were obtained from the Chinese Academy of Sciences). PC9 lung adenocarcinoma cells were from Dr. Takayama (Kyushu University). Gefitinib-resistant PC9/G cells were produced as previously described [@B29]. Briefly, PC9 cells were treated for 24 h with 2.5 μg/ml MNNG followed by treatment with media containing 0.2 μmol/L gefitinib for 7 d. Cells were then grown under normal culture conditions for 14 d. When a substantial number of viable cells were identified, cells were seeded into 96-well plates to obtain single clones from 21 d of culture in the presence of 0.3-0.5 μmol/L gefitinib. Cells were then maintained in 0.05 μmol/L gefitinib under standard culture conditions.

PI3K assessments
----------------

Cells were treated with EGF (ab9697; Abcam) or (ab119139; Abcam). COX-2 was silenced using shRNA approaches (Gene Pharma Co). FLAG-COX2, HA‐EGFR, and the pmyr-AKT were transfected into cells and lentiviruses were isolated. For silencing experiments, the indicated cell lines were infected and PI3K kinase assays were performed as previously described [@B30].

RT-qPCR
-------

RNA was TRIzol extracted and cDNA was synthesized. Gene expression was quantified via RT-qPCR and relative gene expression was assessed using the 2^-ΔΔCt^ method and normalized to GAPDH. Primers used for qRT-PCR are shown in Table [2](#T2){ref-type="table"}.

Cell viability assays
---------------------

Cell viability was assessed in transfected PC9 and PC9/GR cells treated with gefitinib (0-20 μM) for 24 h. Cell viability was assessed in via CCK-8 assays. Absorbances were read at 450 nm. Values were normalized to untreated controls and IC50s were calculated for each treatment.

Cell migration and invasion assays
----------------------------------

For Transwell assays, cells were seeded onto BioCoat Matrigel wells and cell migration and invasiveness were assessed. Migrating/invading cells were quantitated from six microscopic fields. Experiments were performed on 3 or more independent occasions.

Interaction analysis
--------------------

NSCLC cells were harvested in RIPA buffer containing protease inhibitor cocktail as previously described [@B20]. Table [3](#T3){ref-type="table"} shows all primary and secondary antibodies used in the study.

*In vivo* xenograft models
--------------------------

All animal assessments were approved by our internal review board. Male nude mice (n=10, aged 4 weeks, Academy of Military Medical Science, Beijing). Cells in PBS were subcutaneously injected into the flanks to establish tumor models (5×10^6^ cells).

Statistics
----------

Data were analyzed using SPSS 20.0. Data are the mean ± SD (n=3) compared via a two-tailed Student\'s t-test or one-way Anova for multiple group comparisons. A Wilcoxon signed rank test was used for the analysis of variance. Mann Whitney U tests were performed as required. Survival analysis was performed using KM analysis. Patient survival was compared via a log-ranked test. Significant values had P-values \<0.05.

Results
=======

COX-2 is overexpressed in NSCLC tissue and correlates with an unfavorable prognosis
-----------------------------------------------------------------------------------

To assess potential role of COX-2 in NSCLC, RT-qPCR was used to assess COX-2 expression in 32 paired NSCLC samples. COX-2 mRNA was highly expressed in NSCLC vs. healthy lung tissue (Figure [1](#F1){ref-type="fig"}A). In patients resistant to gefitinib, COX-2 mRNA was upregulated vs. gefitinib sensitive patients (Figure [1](#F1){ref-type="fig"}B). In NSCLC cell lines, COX-2 expression at the protein level also increased (Figure [1](#F1){ref-type="fig"}C-D). Gefitinib-resistant cells (PC9/GR) also showed higher COX-2 expression than PC9 cells (Figure [1](#F1){ref-type="fig"}E). GEPIA analysis showed high levels of COX-2 expression in lung adenocarcinoma (LUAD) that correlated with poor patient prognosis (Figure [1](#F1){ref-type="fig"}F). Thus, COX-2 is overexpressed in NSCLC tissue and is a marker of poor prognosis.

COX-2 enhances gefitinib resistance and metastasis in NSCLC cells
-----------------------------------------------------------------

We found that in LUAD cells (PC9), COX-2 was upregulated in a concentration dependent manner by gefitinib (Figure [2](#F2){ref-type="fig"}A). We exogenously overexpressed or silenced COX-2 expression to assess its effects on PC9/GR cells (Figure [2](#F2){ref-type="fig"}B, 2C). CCK-8 assays showed that the IC50 of gefitinib increased in PC9 cells exogenously expressing COX-2 (Figure [2](#F2){ref-type="fig"}D), but decreased in COX-2 silenced cells (Figure [2](#F2){ref-type="fig"}D). Transwell assays showed that the overexpression of COX-2 led to higher levels of cell migration and invasion, whilst the opposite phenotype was observed for COX-2 silenced cells (Figure [2](#F2){ref-type="fig"}E). RT-qPCR analysis showed that COX-2 overexpression enhanced the levels of P-gp, MRP1, and BCRP, which were inhibited following COX-2 silencing (Figure [2](#F2){ref-type="fig"}F). In Xenograft mouse models, COX-2 silencing led to lower tumor volumes and weight in those injected with PC9/GR cells (Figure [2](#F2){ref-type="fig"}G-H). The culmination of these data shows that COX-2 enhances gefitinib resistance, and promotes the metastatic phenotypes of NSCLC cells.

COX-2 enhances gefitinib resistance and NSCLC metastasis through PI3K-AKT silencing
-----------------------------------------------------------------------------------

To investigate the mechanism(s) through which COX-2 mediates gefitinib resistance, we first examined its role in EMT, a key pathway for cancer metastasis. No notable effects of COX-2 on EMT were observed as vimentin, and N-cadherin expression were largely unchanged between COX-2 overexpressing or silenced lines (Figure [3](#F3){ref-type="fig"}A), suggesting that COX-2 mediated metastasis and drug resistance in NSCLC cells is EMT independent. Tumor invasion occurs due to the increased proteolytic activity of MMPs that degenerate neighboring stroma, enabling the spread of tumor cells. MMP-2, -7, and -9 expressions were found to decrease in COX-2 silenced cells (Figure [3](#F3){ref-type="fig"}B). AKT was also inactivated in PC9/ GR cells silenced for COX-2 whilst JNK2, STAT3 and p38 were largely unaffected (Figure [3](#F3){ref-type="fig"}C). In COX-2 silencedPC9/GR cells, the exogenous expression of AKT significantly increased the expression of MMP-2, -7, and -9 at the mRNA level (Figure [3](#F3){ref-type="fig"}D). Enhanced PI3K activity was also observed whilst PTEN expression was largely unaffected (Figure [3](#F3){ref-type="fig"}E, F). The overexpression of AKT led a higher gefitinib IC50 values (Figure [3](#F3){ref-type="fig"}G). In addition, the migration and invasiveness of NSCLC cells increased following AKT overexpression (Figure [3](#F3){ref-type="fig"}H). These data highlight the role of PI3K‐AKT signaling in COX-2 mediated gefitinib resistance in NSCLC cells.

COX-2-binds to EGFR to activate PI3K/AKT signaling
--------------------------------------------------

PI3K/AKT signaling activation in response to RTK stimulation. To investigate the ability of COX-2 to activate RTKs in NSCLC cell lines, cells were stimulated with HGF and EGF. As shown in Figure [4](#F4){ref-type="fig"}A-B, COX-2 silencing prevented EGF stimulated AKT activity in PC9/GR silenced cells vs control shNT cells. In contrast, HGF was unaffected by COX-2 silencing. To investigate a potential interaction between COX-2 and EGFR, FLAG-tagged COX-2 and HA-EGFR were over expressed by transfection in PC9 cells and examined their interaction through co-immunoprecipitation assays. We observed a robust COX-2-EGFR interaction suggestive of its role in COX-2 mediated PI3K signaling (Figure [4](#F4){ref-type="fig"}C). In addition, upon COX-2 silencing, the phosphorylation of TYR992, TYR1045, and TYR1068 in EGFR decreased in PC9/GR cells (Figure [4](#F4){ref-type="fig"}D). The culmination of these data highlights COX-2 as a potent oncogene that enhances the targeted resistance of NSCLC cells through its interaction with EGFR, and subsequent activation of the EGFR/PI3K/AKT axis.

Discussion
==========

Surgical intervention with concomitant chemotherapy remains the front-line treatment for the majority of human cancers [@B31]. The aim of chemotherapy is to eliminate tumor cells following surgical excision of the tumor and to prevent relapse [@B32]. Gefitinib is an EGFR-TKIs that can treat NSCLC patients harboring EGFR mutations [@B33]^.^ Gefitinib is typically administered to patients harboring exon 19 deletions or L858R point mutations [@B34] and displays high levels of antitumor efficacy [@B35]. In the present study, we found that the exogenous expression of COX-2 in NSCLC cells/tissue enhances their resistance to gefitinib therapy.

COX-2 expression increases in NSCLC cells with gefitinib-induced resistance. The higher levels of COX-2 promote metastatic phenotypes in the tumor cells and promote gefitinib resistance, inferring its role as an oncogene and a key mediator of therapeutic resistance. Resistance to gefitinib through various molecular mechanisms is a major barrier to effective targeted therapy.

To investigate the oncogenic effects of COX-2, we assessed its ability to enhance EMT, a key predictor of cancer metastasis [@B36]-[@B39]. Following COX-2 silencing in NSCLC cells, no changes in the expression of known EMT genes were observed. Next, we investigated the effects of COX-2 of an array of known pro-oncogenic signaling pathways. We observed robust AKT activation in COX-2 overexpressing cells and a loss of MMP expression and PI3K signaling upon COX-2 silencing confirming a role for MMPs and AKT in NSCLC metastasis occurrence and development [@B40]-[@B43]. We further demonstrated the ability of COX-2 to bind to the EGFR which, in turn, activated EGFR and enhanced PI3K signaling. No such effects were observed for HGF-HGFR signaling in these cells. This revealed new mechanistic insight into the mechanisms through which COX-2 enhances gefitinib resistance, namely through activation of the EGFR/PI3K/AKT axis.

Most solid tumors display enhanced levels of EGFR expression [@B44]-[@B46]. For NSCLC, the overexpression of EGFR strongly correlates with the clinical histopathological characteristics of patients. The overexpression of EGFR leads to aggressive tumor invasion and as such, EGFR inhibitors can effectively alleviate the malignant characteristics of many tumor cells [@B47]. For NSCLC, emerging preclinical evidence supports the effectiveness of EGFR inhibition as a therapeutic intervention and treatment [@B48]. Our data highlights that compounds targeting the COX-2-EGFR interaction have potential as future NSCLC therapeutics. The mechanism(s) by which COX-2 regulates PI3K-AKT signaling through its interaction with EGFR now require assessment. We speculate that COX-2 promotes PI3K‐AKT activity through the following mechanisms: 1) COX-2 binds to EGFR to prevent its lysosomal degradation, thus enhancing receptor stability; 2) COX-2 promotes the formation of EGFR dimers to enhance signaling capacity; 3) COX-2 inhibits EGFR endocytosis and the subsequent trafficking of the receptor to the lysosomes for degradation. In future studies, we will explore the mechanisms by which COX-2 enhances PI3K‐AKT signaling mediated through EGFR binding.

In summary, we report, for the first time, that COX-2 mediates the gefitinib-resistant of NSCLC cells. Mechanistically, COX-2 was identified as a novel EGFR interacting partner and enhanced PI3K/AKT signaling through this binding. Taken together, these data highlight the interaction between COX-2 and EGFR and the PI3K/AKT axis as a novel therapeutic strategy to overcome gefitinib resistance in NSCLC cells.
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![**COX-2 is overexpressed in NSCLC tissue and correlates with poor patient prognosis. (A)** COX-2 mRNA assessed by qRT-PCR analysis in 32 paired NSCLC tissues. **(B) C**OX-2 mRNA levels in NSCLC patients showing gefitinib resistance vs. gefitinib sensitive patients. **(C)** COX-2 mRNA expression in the NSCLC cells vs control cells analyzed by qRT-PCR. (Mean ± SEM, p ≤0.05). **(D)** COX-2 protein expression in NSCLC cells vs. normal cells. **(E)** COX-2 mRNA and protein expression in PC9/GR (gefitinib resistant) and naive PC9 cells. **(F)** OS according to COX-2 expression assessed through the GEPIA. Two-sided log-rank tests were used to determine p-values.](jcav11p3667g001){#F1}

![**COX-2 promotes gefitinib chemo resistance and the metastatic phenotypes of NSCLC cells. (A)** RT-qPCR showing COX-2 expression in PC9 cells treated with gefitinib. **(B-C)** PC9 cells overexpressing FLAG-COX-2 or silenced for COX-2 expression (KD, shCOX-2\#1, \#2) in PC9 cells (PC9/GR). Data are the mean ± SEM. **(D)** Cell viability assessments and IC50 of gefitinib in PC9 vs. PC9/GR cells. Data were compared through ANOVA analysis. **(E)** Transwell assays to show PC9 and PC9/GR cell invasion. Data were compared via a Student\'s t test. **(F)** P-gp, MRP1, and BCRP expression assessed via RT-qPCR. Data were compared via a Student\'s t test. **(G-H)** Xenograft assays for the assessment of tumor volume and weight in mice subcutaneously injected with PC9 cells. Data are the mean ± SEM. Data were compared via ANOVA assessments.](jcav11p3667g002){#F2}

![**COX-2 influences the expression of tumor cell MMPs through PI3K-AKT signaling. (A)** Vimentin, E‐cadherin and N‐cadherin expression assessed by WB. **(B)** WB analysis of MMP expression in the indicated cell lines. GAPDH was probed as a control. **(C)** WB assessment of p‐AKT, p-STAT3, p-JAK2, and p‐p38 levels in the indicated cells. GAPDH was probed as a loading control. **(D) Relative** mRNA expression of the indicated MMPs. Data are the mean ± SEM, compared through a Student\'s t test. **(E)** PI3K activity and **(F)** PTEN expression on the indicated cell lines. GAPDH was probed as a loading control. **(G)** IC50 of gefitinib in PC9/GR cells co-transfected with COX-2 siRNA and/or AKT overexpression plasmids. Data were compared via a one-way ANOVA. **(H)** Migration and invasion assays. Data are the mean ± SEM compared through a Student\'s t‐test.](jcav11p3667g003){#F3}

![**COX-2-EGFR binding leads to PI3K/AKT activation. (A-B)** Cells were treated with EGF or HGF **(B)** for the indicated time points and WB for the indicated proteins was performed. **(C)** Co-Ip assays of PC9 cells transfected with HA-EGFR, FLAG-COX-2 or empty vector controls. **(D)** Cells were stimulated with EGF exposure for 0 or 15 min and WB analysis was performed as described.](jcav11p3667g004){#F4}

###### 

The Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients

  Characteristics             Patients(number)
  --------------------------- ------------------
  **Gender**                  
  Male                        22
  Female                      10
  **Age (year)**              
  ≤60                         19
  \>60                        13
  **Smoking**                 
  Yes                         15
  No                          17
  **Size of tumor (cm)**      
  ≤3                          20
  \<3                         12
  **Differentiation**         
  Well/moderate               20
  Poor                        12
  **TNM stage**               
  I/II                        19
  III/IV                      13
  **Lymph node metastasis**   
  N0                          18
  N1-3                        14

TNM: Tumor Node Metastasis

###### 

Sequence of Primers for qRT-PCR

  Primer                 Sequence (5\' to 3\')
  ---------------------- ----------------------------
  COX-2 forward primer   TTCCAGATCCAGAGCTCATTAAA
  COX-2 reverse primer   CCGGAGCGGGAAGAACT
  P-gp forward primer    GATCTTGAAGGGGACCGCAATGGA
  P-gp reverse primer    GATGCATAGATCAGCAGGAAAGCAGC
  MRP1 forward primer    CTCCCCGGTCTATTCCCATTTCAA
  MRP1 reverse primer    TCTCGGTAGCGCAGGCAGTAGTTC
  BCRP forward primer    CAGGTGGAGGCAAATCTTCGT
  BCRP reverse primer    ACACACCACGGATAAACTGA
  MMP-2 forward primer   TCTTGACCAGAATACCATCG
  MMP-2 reverse primer   TACTTCACACGGACCACTTG
  MMP-7 forward primer   AGTGGTCACCTACAGGATCGTA
  MMP-7 reverse primer   ATCTCCTCCGAGACCTGTCC
  MMP-9 forward primer   CAACATCACCTATTGGATCC
  MMP-9 reverse primer   GGGTGTAGAGTCTCTCGCTG
  GAPDH forward primer   TGTGGGCATCAATGGATTTGG
  GAPDH reverse primer   ACACCATGTATTCCGGGTCAAT

###### 

The primary antibodies used for WBs and the antibodies used for IP

  Antibody                                 Supplier
  ---------------------------------------- ------------------------------------------
  COX-2                                    ab179800, Abcam, 1:1,000
  GAPDH                                    ab181602, Abcam, 1:1,000
  vimentin                                 ab193555, Abcam,1:1,000
  E-cadherin                               ab194982, Abcam,1:1,000
  N-cadherin                               ab202030, Abcam,1:1,000
  PTEN                                     ab32119, Abcam, 1:1,000
  STAT3                                    ab119352, Abcam,1:1,000
  JAK2                                     ab108596, Abcam,1:1,000
  total p38(T-p38)                         ab31828, Abcam,1:1,000
  total Akt (T-Akt)                        ab179463, Abcam,1:1,000
  phosphorylated EGFR (p-EGFR, at Y992)    ab81440, Abcam, 1:1,000
  phosphorylated EGFR (p-EGFR, at Y1045)   ab24928, Abcam, 1:1,000
  phosphorylated EGFR (p-EGFR, at Y1068)   ab40815, Abcam, 1:1,000
  phosphorylated p38(p-p38)                ab4822, Abcam, 1:1,000
  phosphorylated STAT3(p-STAT3)            ab76315, Abcam, 1:1,000
  phosphorylated JAK2(p-JAK2)              Ab32101, Abcam,1:000
  phosphorylated Akt (p-Akt)               ab38449, Abcam, 1:1,000
  HA-probe                                 sc-2362, Santa Cruz Biotechnology; 1:800
  FLAG-probe                               F1804, Sigma-Aldrich; 1:2,000
  EGFR                                     ab52894, Abcam, 1:1,000
  FLAG M2-affinity gel                     A2220, Sigma-Aldrich; 20 ml per reaction
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